相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Immunology
Rachael K. Raw et al.
Summary: A survey-based study of healthcare workers in Northeast England was conducted to investigate the influence of previous COVID-19 on vaccine-associated adverse events (AEs). The study found that AEs were worse after the first dose of the vaccine in individuals with prior COVID-19, but the second dose had greater frequency and severity of AEs regardless of COVID-19 history. Women and younger healthcare workers were more likely to report AEs after both doses, while dosing interval did not affect AEs. Ongoing symptomatic COVID-19 was associated with greater frequency and severity of AEs after the second dose. Overall, the AEs were self-limiting and short-lived in nature.
Review
Obstetrics & Gynecology
Alexander M. Kotlyar et al.
Summary: The study found that 3.2% of 936 neonates from mothers with coronavirus disease 2019 tested positive for severe acute respiratory syndrome coronavirus 2 viral RNA using nasopharyngeal swab. The rates of infection are similar to those of other pathogens causing congenital infections but further research is needed to determine the rates of vertical transmission in early pregnancy and potential risk for fetal morbidity and mortality.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Obstetrics & Gynecology
R. Orefice
Summary: The human immune system consists of two defense components: innate and humoral immunity, which cooperate to protect the body from foreign organisms. Defects or malfunctions in these systems can lead to various illnesses. During pregnancy, there are immune shifts to promote maternal-fetal tolerance, indicating that the immune system is modulated rather than suppressed.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
(2021)
Review
Obstetrics & Gynecology
Deemah Salem et al.
Summary: Pregnant women who are COVID-19 positive are typically asymptomatic or exhibit mild-to-moderate symptoms, similar to non-pregnant women. Pneumonia is a common outcome in pregnant women with COVID-19. While there are increased risks for pregnant women with co-morbidities, it is still uncertain whether SARS-CoV-2 infection raises the risk of complications for mothers, fetuses, and newborns.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2021)
Review
Public, Environmental & Occupational Health
Nicoletta Luxi et al.
Summary: While the benefit-risk profile of the four authorized COVID-19 vaccines has been largely favorable in the general population, evidence remains limited for special cohorts such as pregnant women, children, immunocompromised individuals, and those with a history of allergies or previous SARS-CoV-2 infection. This narrative review critically examines the potential benefits and risks of COVID-19 vaccines in these special cohorts, and summarizes recommendations from scientific societies and regulatory agencies for primary prevention in these vaccinee categories.
Review
Virology
Maryamsadat Jafari et al.
Summary: Pregnant women infected with COVID-19 exhibit similar symptoms to non-pregnant adult patients, with a higher likelihood of fever and fatigue and a lower likelihood of cough, headache, and diarrhea. Ground-glass opacity is the most common imaging finding in pregnant women, while consolidation is more common in non-pregnant patients. Pregnant patients have a lower risk of vertical transmission.
REVIEWS IN MEDICAL VIROLOGY
(2021)
Letter
Medicine, General & Internal
Florian Krammer et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Tamar Wainstock et al.
Summary: The study found that prenatal administration of the Pfizer-BioNTech COVID-19 vaccine has no adverse effects on pregnancy course and outcomes. Women who received the vaccine during pregnancy were typically older, more likely to conceive following fertility treatments, and received more prenatal care, but there were no significant differences in pregnancy, delivery, or newborn complications compared to unvaccinated women.
Article
Medicine, General & Internal
Shu Qin Wei et al.
Summary: Infection with COVID-19 during pregnancy may lead to an increased risk of preeclampsia, preterm birth, and other adverse pregnancy outcomes. Severe cases of COVID-19 are particularly associated with higher risks of complications such as preeclampsia, preterm birth, gestational diabetes, and low birth weight.
CANADIAN MEDICAL ASSOCIATION JOURNAL
(2021)
Article
Nursing
Karoline Faria de Oliveira et al.
Summary: Most studies focused on pregnant women over the age of 30 who were infected in the third trimester of pregnancy and had comorbidities. The prematurity index varied due to sample heterogeneity, and cases of abortion were related to severe infection. Cesarean section deliveries predominated, mainly due to respiratory decompensation caused by infection. Most women were discharged.
INTERNATIONAL JOURNAL OF NURSING PRACTICE
(2021)
Article
Immunology
Aurelie Baldolli et al.
Summary: The study found that individuals with a history of COVID-19 infection are more likely to experience systemic reactions and symptoms like fatigue, headache, and fever after receiving the BNT162b2 mRNA Covid-19 vaccine. Although these individuals had higher severity of reactions, overall tolerance was good.
Review
Immunology
Lydia L. Shook et al.
Summary: The COVID-19 pandemic has highlighted the urgent need to develop vaccine strategies optimized for pregnant people and their newborns, even though pregnant individuals were not included in vaccine trials but have had access to them since release. The rapid distribution of COVID-19 vaccines to at-risk individuals, including pregnant and lactating women, provides an unprecedented opportunity to understand vaccine-induced immunity in these populations.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Review
Medicine, General & Internal
Gilbert G. G. Donders et al.
Summary: Pregnancy is considered a risk factor for serious complications of COVID-19 infection, even without additional risk factors present. Current data slightly favor mRNA-based vaccines over vector-based vaccines for pregnant and breastfeeding women, until more safety data becomes available. Policy makers and societies are advised to prioritize pregnant women for SARS-CoV-2 vaccination and to recommend mRNA vaccines until further safety information is obtained.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Jose Javier Morales-Nunez et al.
Summary: The study evaluated the efficacy of the Pfizer-BioNTech vaccine in producing neutralizing antibodies, finding 100% production after the second dose in both groups and well-tolerated side effects. Additionally, a single dose of the vaccine may be sufficient for immunity in individuals with prior COVID-19 infection, with possible signs of immunosenescence.
Article
Immunology
Wojciech Zdanowski et al.
Summary: This study aimed to evaluate the transfer of antibodies between mothers and infants after COVID-19 vaccination during pregnancy. The results showed high levels of antibodies in all analyzed mother-infant pairs, with a correlation between antibody transfer and the timing of vaccination to delivery.
Correction
Medicine, Research & Experimental
Ofer Beharier et al.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Obstetrics & Gynecology
Regan N. Theiler et al.
Summary: In this study, pregnant women who received COVID-19 vaccination were less likely to contract COVID-19 compared to those who did not receive the vaccine, and vaccination during pregnancy did not lead to increased risks of pregnancy or delivery complications. Factors such as older age, higher education level, non-smoking status, use of infertility treatment during current pregnancy, and lower gravidity were associated with a higher likelihood of vaccination.
AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY MFM
(2021)
Article
Medicine, General & Internal
Yun Woo Lee et al.
Summary: This study found that the rate of adverse reactions in healthcare workers after receiving both doses of the BNT162b2 mRNA vaccine significantly increased after the second dose, especially muscle ache, fatigue, headache, chills, and fever. Females had a significantly higher frequency of adverse reactions after the second dose, while older age groups had lower rates of adverse reactions.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2021)
Review
Medicine, General & Internal
Chiu-Lin Wang et al.
Summary: COVID-19, caused by SARS-CoV-2, is an emerging disease that has rapidly spread worldwide since its identification in Wuhan, China, in December 2019. Limited data on the clinical characteristics of pregnant women with COVID-19 have been reported, raising concerns about their risk of infection and clinical outcomes.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Article
Public, Environmental & Occupational Health
Lindsay Kim et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2020)
Review
Immunology
Emily F. Cornish et al.
FRONTIERS IN IMMUNOLOGY
(2020)
